Expression of aspartoacylase (ASPA) and Canavan disease

Gene

Volumn 505, Issue 2, 2012, Pages 206-210

  Sommer, Anke ^a   Sass, Jörn Oliver ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Aminoacylase; Aspartoacylase; Canavan disease; Inborn error of metabolism; N acetyl l aspartic acid; Organic aciduria

Indexed keywords

ASPARTOACYLASE; MESSENGER RNA;

ARTICLE; BRAIN; CANAVAN DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY; LIVER; LUNG; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION;

AMIDOHYDROLASES; BASE SEQUENCE; BRAIN; CANAVAN DISEASE; GENE EXPRESSION; HEK293 CELLS; HUMANS; KIDNEY; LIVER; LUNG; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 84864136029     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.06.036     Document Type: Article

References (36)

1. Baslow M.H. N-acetyl aspartate in the vertebrate brain: metabolism and function. Neurochem. Res. 2003, 28:941-953.
2. Baslow M.H., Suckow R.F., Sapirstein V., Hungund B.L. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. J. Mol. Neurosci. 1999, 13:47-53.
3. Beaudet A.L. Aspartoacylase deficiency (Canavan disease). The Metabolic and Molecular Bases of Inherited Disease 2001, vol. 4:5799-5803. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
4. Birnbaum S.M., Levintow L., Kingsley R.B., Greenstein J.P. Specificity of amino acid acylases. J. Biol. Chem. 1952, 194:455-470.
5. Bitto E., Bingman C.A., Wesenberg G.E., McCoy J.G., Phillips G.N. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:456-461.
6. D'Adamo A.F., Smith J.C., Woiler C. The occurrence of N-acetyl aspartate amidohydrolase (aminoacylase II) in the developing rat. J. Neurochem. 1973, 20:1275-1278.
7. Di Pietro V., et al. A new T677C mutation of the aspartoacylase gene encodes for a protein with no enzymatic activity. Clin. Biochem. 2008, 41:611-615.
8. Feigenbaum A., et al. Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am. J. Med. Genet. A 2004, 124A:142-147.
9. Geisse S., Henke M. Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production. J. Struct. Funct. Genomics 2005, 6:165-170.
10. Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 1981, 23:175-182.
11. Hershfield J.R., Madhavarao C.N., Moffett J.R., Benjamins J.A., Garbern J.Y., Namboodiri A. Aspartoacylase is a regulated nuclear-cytoplasmic enzyme. FASEB J. 2006, 20:2139-2141.
12. Hershfield J.R., Pattabiraman N., Madhavarao C.N., Namboodiri M.A. Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res. 2007, 1148:1-14.
13. Janson C.G., et al. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene. Ann. Neurol. 2006, 59:428-431.
14. Kaul R., Gao G.P., Balamurugan K., Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat. Genet. 1993, 5:118-123.
15. Kaul R., Balamurugan K., Gao G.P., Matalon R. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 1994, 21:364-370.
16. Kaul R., et al. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am. J. Hum. Genet. 1996, 59:95-102.
17. Kronn D., Oddoux C., Phillips J., Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am. J. Hum. Genet. 1995, 57:1250-1252.
18. Le Coq J., An H.J., Lebrilla C., Viola R.E. Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease. Biochemistry 2006, 45:5878-5884.
19. Le Coq J., Pavlovsky A., Malik R., Sanishvili R., Xu C., Viola R.E. Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 2008, 47:3484-3492.
20. Lienhard U., Sass J.O. Canavan disease, a neurometabolic disease caused by aspartoacylase deficiency. J. Pediatr. Sci. 2011, 3:e71.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
22. Madhavarao C.N., Moffett J.R., Moore R.A., Viola R.E., Namboodiri M.A., Jacobowitz D.M. Immunohistochemical localization of aspartoacylase in the rat central nervous system. J. Comp. Neurol. 2004, 472:318-329.
23. Makarova K.S., Grishin N.V. The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J. Mol. Biol. 1999, 292:11-17.
24. Matalon R., Michals K., Sebesta D., Deanching M., Gashkoff P., Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am. J. Med. Genet. 1988, 29:463-471.
25. Matalon R., et al. Prenatal diagnosis for Canavan disease: the use of DNA markers. J. Inherit. Metab. Dis. 1995, 18:215-217.
26. Moore R.A., Le Coq J., Faehnle C.R., Viola R.E. Purification and preliminary characterization of brain aspartoacylase. Arch. Biochem. Biophys. 2003, 413:1-8.
27. Namboodiri M.A., Corigliano-Murphy A., Jiang G., Rollag M., Provencio I. Murine aspartoacylase: cloning, expression and comparison with the human enzyme. Brain Res. Mol. Brain Res. 2000, 77:285-289.
28. Shaag A., et al. The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am. J. Hum. Genet. 1995, 57:572-580.
29. Shu X., Liu Y., Yang L., Song C., Hou J. Isolation, sequence identification and tissue expression profiles of 3 novel porcine genes: ASPA, NAGA, and HEXA. J. Appl. Genet. 2008, 49:257-261.
30. Sistermans E.A., de Coo R.F., van Beerendonk H.M., Poll-The B.T., Kleijer W.J., van Oost B.A. Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population. Eur. J. Hum. Genet. 2000, 8:557-560.
31. Sommer A., et al. The molecular basis of aminoacylase 1 deficiency. Biochim. Biophys. Acta 2011, 1812:685-690.
32. Surendran S., Bamforth F.J., Chan A., Tyring S.K., Goodman S.I., Matalon R. Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem. J. Child Neurol. 2003, 18:809-812.
33. Surendran S., Szucs S., Tyring S.K., Matalon R. Aspartoacylase gene knockout in the mouse: impact on reproduction. Reprod. Toxicol. 2005, 20:281-283.
34. Tacke U., et al. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics 2005, 36:252-255.
35. Traka M., Wollmann R.L., Cerda S.R., Dugas J., Barres B.A., Popko B. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. J. Neurosci. 2008, 28:11537-11549.
36. Zeng B.J., et al. Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease. J. Inherit. Metab. Dis. 2002, 25:557-570.